Eris Lifesciences redeems INR 437.5 crore in debentures
Eris Lifesciences Limited (BSE: ERIS) announced the redemption of 43,750 secured unlisted redeemable non-convertible debentures (NCDs) aggregating to ₹437.50 crore (Rupees Four Hundred Thirty-Seven Crore And Fifty Lakh only). The debentures, identified by ISIN INE406M07013, were redeemed on February 21, 2025. The company stated the redemption aligns with the terms of the applicable agreements. These debentures were initially issued as part of the consideration for the acquisition of Swiss Parenteral Limited on February 13, 2024. The redemption will not significantly alter the company's aggregate debt position. The announcement was made to the Bombay Stock Exchange and National Stock Exchange of India, in compliance with regulatory requirements.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when Eris Lifesciences publishes news
Free account required • Unsubscribe anytime